Abstract:ID 97320 Poster Board 473 For the 46 million African Americans in the United States, nearly 14 million representing ~30% of black population suffer from cardiovascular disease. Importantly, a genetic variant in aldehyde dehydrogenase 2 (ALDH2), commonly known as ALDH2*2 (rs671, E504K) exclusively present in 560 million East Asians is a risk factor for cardiovascular disease in Asians. The ALDH2*2 variant is associated with reduced ALDH2 enzymatic activity in vitro and in vivo , and leads to acetaldehyde accumulation following alcohol consumption. However, it is not well understood whether ALDH2 genetic variants carried by the Black population leads to impaired acetaldehyde metabolism after alcohol intake. Here we hypothesize that ALDH2 variants carried by Blacks can lead to impaired acetaldehyde metabolism in vitro . To test this hypothesis, we discovered using a worldwide Genome Aggregation Database, gnomAD, that ALDH2 variants also exist in Blacks. Here we identified eight Black ALDH2 variants in the gnomAD database which we characterized in vitro . As an initial step, we constructed the variants by site directed mutagenesis, expressed, purified and tested their enzymatic activity to metabolize acetaldehyde. Our in vitro results showed that K155T and R268C ALDH2 proteins are essentially inactive (0.03±0.01 and 0.01±0.00 versus 1.52±0.14 mmol/min/mg for wild-type protein). V80A, F87L and R95C had significantly reduced enzymatic activity relative to the wild type (0.11±0.03, 0.22±0.03 and 0.15±0.06 versus 1.52±0.14 mmol/min/mg for wild-type protein). In addition, I41V, R103W and D299N exhibited 50-70% wild type activity (1.13±0.10, 0.84±0.07 and 0.80±0.16 versus 1.52±0.14 mmol/min/mg for wild-type protein). Furthermore, wild type (3.31±0.22 versus 1.52±0.14 mmol/min/mg for untreated protein), I41V (2.86±0.13 versus 1.13±0.10 mmol/min/mg for untreated protein), V80A (0.33±0.05 versus for 0.11±0.03 mmol/min/mg for untreated protein), F87L (0.76±0.10 versus 0.22±0.03 mmol/min/mg for untreated protein), R103W (2.21±0.31 versus 0.84±0.07 mmol/min/mg for untreated protein), and D299N (2.68±0.30 versus 0.80±0.16 mmol/min/mg for untreated protein) were significantly stimulated by the ALDH2 activator Alda-1. A similar stimulation trend was observed with sodium pyruvate. However, R95C, R168C and K155T were not significantly stimulated by Alda-1 and pyruvate. Together, we identified new Black ALDH2 variants with reduced enzymatic activity. Alda-1 and pyruvate stimulated some but not all variants indicating that Alda-1 and pyruvate are not universal activators of ALDH2 variants. The identification of Black ALDH2 variants with reduced activity is an important step since the reduced activity of ALDH2 variants is linked to cardiovascular disease in Asians. This work was supported by NIH R35GM119522 (ERG) Genetic variants of ALDH2 found in Blacks cause inefficient acetaldehyde metabolism . The activity of wild type ALDH2 and Black ALDH2 variants were measured in the presence of 20μM Alda-1 or 1mM sodium pyruvate or vehicle. Alda-1 significantly activated wild type, I41V, F87L and D299N by 2.2-3.4-fold but did not significantly activate K155T relative to vehicle. Pyruvate significantly activated I41V and D299N by 1.6-2.3-fold but not F87L and K155T relative to vehicle, n=5/group, ^ p<0.01 with unpaired two-tailed Student's t-test relative to untreated.

Contribution of a dysfunctional variant of ALDH4A1 to Alzheimer’s Disease pathology through altered metabolism and mitochondrial impairment

Characterization of the Molecular Mechanisms Underlying Increased Ischemic Damage in the Aldehyde Dehydrogenase 2 Genetic Polymorphism Using a Human Induced Pluripotent Stem Cell Model System.

The aldehyde dehydrogenase 2 rs671 variant enhances amyloid β pathology

Impact of common ALDH2 inactivating mutation and alcohol consumption on Alzheimer's disease

Mitochondrial Aldehyde Dehydrogenase (ALDH2) Rescues Cardiac Contractile Dysfunction in an APP/PS1 Murine Model of Alzheimer's Disease Via Inhibition of ACSL4-dependent Ferroptosis.

Mitochondrial aldehyde dehydrogenase (ALDH2) rescues cardiac contractile dysfunction in an APP/PS1 murine model of Alzheimer’s disease via inhibition of ACSL4-dependent ferroptosis

Further delineation of the phenotypic and metabolomic profile of ALDH1L2‐related neurodevelopmental disorder

Novel aldehyde dehydrogenase 2 variants in Blacks affect acetaldehyde metabolism in vitro

Deficiency in a mitochondrial aldehyde dehydrogenase increases vulnerability to oxidative stress in PC12 cells

Aldh2(E487k) Mutation Increases Protein Turnover and Promotes Murine Hepatocarcinogenesis

Glu504Lys Single Nucleotide Polymorphism of Aldehyde Dehydrogenase 2 Gene and the Risk of Human Diseases

Identifying the Molecular Drivers of Pathogenic Aldehyde Dehydrogenase Missense Mutations in Cancer and Non-Cancer Diseases

Comparative genomics of aldehyde dehydrogenase 5a1 (succinate semialdehyde dehydrogenase) and accumulation of gamma-hydroxybutyrate associated with its deficiency

Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression.

Increasing hexokinase 1 expression improves mitochondrial and glycolytic functional deficits seen in sporadic Alzheimer's disease astrocytes

A common East-Asian ALDH2 mutation causes metabolic disorders and the therapeutic effect of ALDH2 activators

Impaired Mitochondrial Energy Metabolism Regulated by p70S6K: A Putative Pathological Feature in Alzheimer's Disease

Glyceraldehyde-3-phosphate dehydrogenase is involved in the pathogenesis of Alzheimer's disease

Haploinsufficiency of lysosomal enzyme genes in Alzheimer’s disease

Over‐expression of N‐acetylaspartate synthase exacerbates pathological energetic deficit and accelerates cognitive decline in the 5xFAD mouse

ALDH2 mutations and defense against genotoxic aldehydes in cancer and inherited bone marrow failure syndromes